Science and Research

A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.

To compare the efficacy of otilimab 90 mg IV versus placebo

Study details
Study-ID: 2020-001759-42
Study-ID: 2020-001759-42
DZL Disease Area: PALI
DZL Disease Area: PALI
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BREATH
DZL Participating Sites: BREATH
Start Date: 30.04.2021
Completion Date: 01.07.2021
Status: Closed
Status: Closed
DZL recruiting center


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.